Top Banner
Wayne Powell Chief Science Officer CGIAR Consortium Montpellier, May 25 th 2016 Ongoing Business & New Portfolio: a snapshot from the CO Science Team’s perspective
12

Ongoing business & New portfolio - Wayne Powell

Apr 14, 2017

Download

Science

Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Ongoing business & New portfolio - Wayne Powell

Wayne Powell

Chief Science Officer CGIAR Consortium

Montpellier, May 25th 2016

Ongoing Business & New Portfolio: a snapshot from the CO Science Team’s perspective

Page 2: Ongoing business & New portfolio - Wayne Powell

Maintaining Momentum & Focus

• CGIAR Research Programs Annual Reports

• CRPs Plan Of Work & Budget (POWBs)

• CGIAR Annual Report

Page 3: Ongoing business & New portfolio - Wayne Powell

1st MEL CoP meeting (Rome, 10-11 November 2015)

Page 4: Ongoing business & New portfolio - Wayne Powell

The CGIAR Portfolio 2017+

Page 5: Ongoing business & New portfolio - Wayne Powell

Summary inputs provided by the Consortium Office to the ISPC review of CRP and Platform Full Proposals

• A report on the Investment/Value for Money analysis that was performed on CRP full proposal submissions

• Some general perspectives on the CRP and Platform full proposal submissions

a) Partnership and CapDev strategies

b) Intellectual Assets

c) Open Access

d) Governance

Page 6: Ongoing business & New portfolio - Wayne Powell

CRP Portfolio overall well positioned to deliver

Page 7: Ongoing business & New portfolio - Wayne Powell
Page 8: Ongoing business & New portfolio - Wayne Powell
Page 9: Ongoing business & New portfolio - Wayne Powell
Page 10: Ongoing business & New portfolio - Wayne Powell
Page 11: Ongoing business & New portfolio - Wayne Powell
Page 12: Ongoing business & New portfolio - Wayne Powell

CO Observations on the proposed Portfolio

1. Is there sufficient capacity and capability to deliver on the ambitious goals?

2. Are Partnership opportunities, including the Private sector being fully leveraged?

3. Strategic allocation of W1/W2 funds?

4. Capital investment and infrastructure to support a 900 million USD per annum portfolio?

5. Integration of natural, physical and social sciences, will the big data platform enable such integration?

6. Genetic gain/Genebanks platforms considerable overlap in terms of goals should they be combined?